Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Atara Biotherapeutics faces a class action securities fraud lawsuit after the FDA rejected its Epstein-Barr virus treatment (tabelecleucel/EBVALLO) twice due to manufacturing issues and inadequate trial design. The stock plummeted 40.5% on January 16, 2025, and another 57% on January 12, 2026, following the rejections. Shareholders who purchased ATRA securities between May 20, 2024 and January 9, 2026 are urged to file lead plaintiff motions by May 22, 2026.